Skip to main content

Market Overview

Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics

  • Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products using next-generation sequencing technology to complement Inovio's therapies.
  • The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from the clinical use of VGX-3100, INO's immunotherapy, to treat advanced cervical dysplasia associated with the human papillomavirus (HPV).
  • VGX-3100 is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2) as a non-surgical treatment for advanced precancerous cervical lesions associated with HPV-16 and HPV-18.
  • Last month, the company announced that VGX-3100 showed positive efficacy in the Phase 2 Vulvar Dysplasia study. 25% or more reduction in HPV-16/18-associated vulvar lesions was observed for 63% of trial participants at six months post-treatment.
  • In Phase 2 Anal Dysplasia study, VGX-3100 showed resolution of precancerous anal lesions in 50% (11 of 22) of subjects six months following the start of treatment.
  • Price Action: INO is up 4.3% at $12.18, while QGEN is down 2.75% at $51.97 in premarket trading on the last check Wednesday.

Related Articles (INO + QGEN)

View Comments and Join the Discussion!

Posted-In: cervical dysplasia human papillomavirusBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at